Racura Oncology (RAC) Status Update summary

Scientific discovery and patent development

• Identified that bisantrene exists as three photoisomers, with only the EE form showing significant anticancer activity across a broad range of cancer cell lines, while EZ and ZZ forms are largely inactive.

• Discovery led to the filing of three patents covering the chemical structure, manufacturing process, and formulation of pure EE bisantrene, aiming for 20 years of composition of matter protection, potentially extendable to 25 years.

• Innovative manufacturing methods were developed to produce high-purity EE bisantrene at scale, overcoming challenges with previous synthesis techniques.

• Regulatory agencies strongly prefer pure isomer formulations due to safety, efficacy, and side effect profiles, making the move from mixtures to pure EE critical for approval and commercial value.

• Historical examples like Plavix and Lexapro demonstrate the immense commercial value of patenting pure active isomers.

Commercial and strategic implications

• The new patents create a robust barrier to generic competition, securing exclusivity and supporting premium pricing for up to 20–25 years.

• Both RC110 and RC220 formulations use EE bisantrene, with RC110 showing strong response rates in AML and being phase three ready, a rare combination with long patent life.

• The company is actively engaging in business development, with a focus on building value through data accumulation and robust IP before finalizing partnerships.

• Asia-Pacific, especially China, is seen as a promising region for initial partnering due to local trial data and market size, with ongoing discussions and conference participation.

• Accelerated patent review in Australia is expected to take about eight weeks, with expedited assessment providing early feedback on patentability.

Operational and clinical considerations

• Strict protocols are in place to ensure only EE bisantrene is administered in clinical trials, with light exposure being the key factor in isomer conversion, not body temperature.

• The toxicity and side effect profiles of the inactive isomers are not a concern since only EE is used in formulations; regulatory focus is on minimizing extraneous compounds.

• The company maintains confidentiality and strategic timing in patent filings to maximize IP lifespan and value.

• Ongoing communication with shareholders and potential partners is prioritized, with updates provided as milestones are reached and regulatory requirements met.